Description: Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252, a POZ conjugate for the treatment of Parkinson's disease. The company also develops SER 227 for long-acting pain relief; SER 214 to treat Parkinson's disease; and SER 228 for the treatment of epilepsy. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. Serina Therapeutics, Inc. was founded in 2006 and is based in Huntsville, Alabama.
Home Page: serinatherapeutics.com
601 Genome Way
Huntsville,
AL
35806
United States
Phone:
256 327 9630
Officers
| Name | Title |
|---|---|
| Mr. Steven A. Ledger | CEO & Director |
| Dr. Randall W. Moreadith M.D., Ph.D. | Chief Development Officer |
| Dr. Balkrishan Gill Ph.D. | Executive Chairman |
| Dr. Srini Tenjarla | Senior Vice President of Chemistry, Manufacturing & Controls and Formulation |
Exchange: NYSE MKT
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 46 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 18.0288 |
| IPO Date: | 2018-11-29 |
| Fiscal Year End: | December |
| Full Time Employees: | 9 |